How does Mativ Holdings, Inc. stack up against large industrial rivals and nimble niche players?
The competitive position of Mativ Holdings, Inc. matters because its shift from specialty paper to technical materials faces pressure from scale leaders and agile innovators. In 2025 Mativ reported strategic wins in filtration and healthcare that merit close attention.

Mativ must out-differentiate on tech and sustainability as rivals gain market share; see Mativ SWOT Analysis for specifics.
Where Does Mativ Stand Against Rivals?
Mativ Holdings, Inc. competes as a diversifying challenger in specialty materials, focused on premium, mission-critical solutions rather than commodity scale; FY 2025 revenue was 1.99 billion USD, signaling mid-cap reach that matters to customers needing technical depth over lowest price.
Mativ positions as a premium provider in filtration, specialty films, nonwovens, and adhesives, not a low-cost operator. It competes with larger diversified materials groups on technical capability and with mid-cap peers on specialized product breadth.
With 1.99 billion USD revenue in FY 2025 and operations across North America, Europe, and Asia, Mativ lacks the scale of 3M or DuPont but exceeds many regional competitors in technical portfolio and manufacturing footprint.
Mativ concentrates on Filtration & Advanced Materials (FAM) and Sustainable & Adhesive Solutions (SAS), serving healthcare, industrial, and packaging customers who pay for performance and regulatory compliance.
After divesting Engineered Papers, Mativ is reallocating capital to higher-growth FAM and SAS segments; FY 2025 showed 2.5 percent organic sales growth and an adjusted EBITDA margin of 11.3 percent, despite a 411.9 million USD goodwill impairment that reflects tightened valuation of past acquisitions.
Competitive landscape snapshot: rivals include global titans 3M and DuPont on scale and R&D, label and adhesive specialists like Avery Dennison and Berry Global in packaging and converting, and regional nonwovens/filtration firms for specific end markets; see Who Owns Mativ Company for corporate context: Who Owns Mativ Company
Mativ SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
Who Is Mativ Really Up Against?
Mativ Holdings, Inc. faces direct technical rivals in filtration and global packaging leaders in adhesives and liners, plus disruptive bio-based and specialty-chemical substitute threats. The split of FY 2025 revenue-39% FAM and 61% SAS-frames a two-front competitive landscape where material innovation and sustainability drive the contest.
Hollingsworth & Vose, Donaldson Company, and Ahlstrom-Munksjo challenge Mativ in Filtration & Advanced Materials on technical filtration media and nonwovens; 3M competes across high-margin specialty films and filtration with scale and R&D spend.
Avery Dennison and Berry Global pressure Mativ in Sustainable & Adhesive Solutions on release liners and packaging; Covestro and bio-based startups create substitute threats with biodegradable and animal-free chemistries.
Competition centers on technology and product performance (filtration efficiency, barrier properties), sustainability credentials, and scale-driven cost efficiency; brand and supply-chain reach matter for large OEM contracts.
3M is the most consequential rival given its R&D budget, global reach, and presence across filtration, specialty films, and adhesives-pressuring Mativ on both FAM and SAS fronts.
Pressure is strongest in sustainable packaging and high-performance filtration: customers demand lower carbon footprint materials, higher filtration efficiency, and integrated converting services-areas where Avery Dennison, Berry Global, and 3M compete intensely.
Winning on sustainability and material science determines margin expansion and contract wins; if Mativ lags, market share can shift to larger incumbents or fast-moving bio-based entrants, affecting FY 2026 top-line recovery and pricing power.
For context on strategy and positioning see What Mativ Company Stands For
Mativ PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What Helps Mativ Hold Its Ground?
Mativ Holdings, Inc. defends market position through a global manufacturing footprint and active balance-sheet repair, focusing on mission-critical end markets that raise customer switching costs.
Operating 34 production sites across three continents and selling into over 100 countries gives Mativ a distribution moat that smaller rivals cannot match, helping on-costs and lead times.
Customers in healthcare and aerospace rely on certified, high-barrier materials; switching risks regulatory requalification and supply disruption, so buyers stick with proven suppliers.
Technical coatings and specialty nonwovens for regulated end markets, plus global converting capacity, create an ecosystem advantage versus niche Mativ competitors in packaging and adhesives.
Post-merger integration and a restructuring program targeting USD 55-60 million annual savings by end-2026 improve margins and cash flow resilience during weak demand.
High leverage remains a pressure point: net debt declined ~45% since the Neenah merger but net leverage stood at 4.2x at end-2025, leaving vulnerability to interest-rate and demand shocks.
The combination of global footprint, focus on high-barrier healthcare and aerospace applications, and active deleveraging gives Mativ the strongest practical defense against Mativ competitors and alternatives to Mativ suppliers in packaging and specialty films.
For related go-to-market context see How Mativ Company Sells
Mativ SOAR Analysis
- Complete SOAR Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
Where Is Mativ's Competitive Battle Heading?
The competitive battle for Mativ Holdings, Inc. is shifting toward sustainable chemistry and high-performance lightweight materials; Mativ looks likely to defend near-term ground but must capture sustainable materials share to strengthen long-term. Operational efficiency and debt reduction will hold performance in 2026, yet growth hinges on SAS segment transformation and FAM momentum.
Specialty materials demand is moving to bio-based chemistries and lighter, high-strength films for EV and aerospace; Mativ's fight is to convert its SAS (surfaces and specialty additives) lineup and scale FAM (flexible and adhesion materials) wins into sustainable product revenue.
- Strongest support: Q4 2025 FAM EBITDA rose 26 percent, showing pricing and mix resilience.
- Main pressure point: SAS needs rapid pivot to bio-based chemistries to match market tailwinds in sustainable packaging and automotive.
- Likely near-term direction: defend via cost, efficiency, and debt paydown while selectively investing in sustainable R&D and capacity.
- Clearest competitive takeaway: long-term upside depends on capturing high-growth sustainable materials share, not cost-cutting alone.
Demand for specialty materials is expanding: the market is projected from USD 260.04 billion in 2025 to USD 283.03 billion in 2026 at an 8.8 percent CAGR, driven by EV and aerospace. If Mativ shifts SAS to bio-based polymers and scales lighter, high-strength films, it can convert existing customers in packaging and medical into higher-margin sustainable supply contracts.
Competitors with deeper sustainable-chemistry IP and larger scale-such as legacy global suppliers in specialty films and adhesives-can out-invest Mativ in R&D and capacity. Failure to pivot SAS quickly would leave Mativ exposed despite FAM strength, limiting market-share gains in high-growth segments like sustainable packaging and EV components.
Shift: raw-material innovation from petrochemical to bio-based and recycled feedstocks, plus demand for lightweight composites in EV/aerospace. Companies that combine sustainable polymer chemistry, thin-gauge high-performance films, and global converting capabilities will win share in packaging, medical, and industrial tapes.
Outlook for 2025/2026: mixed but defensible-Mativ should maintain margins via efficiency and debt reduction in 2026, while long-term value depends on SAS conversion to sustainable materials and sustaining FAM growth; market-share gains will be modest without targeted investments.
Relevant competitive context: investors and procurement teams evaluating Mativ competitors and companies that compete with Mativ should compare Mativ vs 3M, Mativ vs Berry Global comparison for packaging solutions, and Avery Dennison vs Mativ vs 3M comparison when assessing alternatives to Mativ suppliers and which companies compete with Mativ in North America, Europe and Asia. See Who Mativ Company Serves for customer focus and positioning: Who Mativ Company Serves
Mativ VRIO Analysis
- Covers VRIO Analysis in Details
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
Frequently Asked Questions
Mativ competes with several large and specialized players. The article names 3M and DuPont as scale rivals, while Avery Dennison and Berry Global compete in packaging and converting. Regional nonwovens and filtration firms also challenge Mativ in specific end markets.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.